Audicin raises $1.9 million to scale brainwave-based nervous system regulation technology

European neurotechnology attracts growing investor interest as wellness meets wearables

The intersection of neuroscience and consumer technology is emerging as one of Europe’s more compelling deep tech investment themes, as advances in brainwave entrainment, biometric integration, and auditory engineering create new commercial pathways for technologies that were previously confined to clinical research settings. With the global wellness technology market expanding rapidly, startups that can bridge the gap between peer-reviewed neuroscience and scalable consumer products are drawing increasing attention from strategic and institutional investors.

Helsinki-based Audicin has raised $1.9 million (€1.6 million) to scale its real-time nervous system regulation technology across defence, healthcare, and enterprise applications. The round includes private investment, follow-on backing from Petteri Lahtela and Virpi Tuomivaara — the co-founders of Oura Health, one of Finland’s most successful consumer health companies — and a grant from Business Finland through its Deep Tech Accelerator programme. The capital brings Audicin’s total funding to approximately $3 million.

Oura Health co-founders double down on brainwave entrainment technology

The continued involvement of the Oura Health co-founders is a notable signal for Audicin’s commercial trajectory. Oura, which pioneered the smart ring category and has become a global standard in passive health monitoring, provides both a strategic reference point and a potential integration pathway for Audicin’s technology. The follow-on investment suggests that the Oura founders see material alignment between Audicin’s nervous system regulation capabilities and the broader ecosystem of wearable health devices.

Audicin’s technology draws on brainwave entrainment, music neuroscience, and auditory engineering to deliver audio-based interventions that support nervous system regulation. Unlike mindfulness applications that require active user engagement, Audicin’s approach works through passive background listening — audio sessions adapted to a user’s physiological signals play in the background while they work, commute, or rest, requiring no conscious effort from the user.

The company’s SDK, Audicin for Apps, enables third-party digital health, performance, and consumer platforms to integrate the technology directly, triggered by biometric data, time of day, or in-app events. The SDK supports integration with leading wearables including Oura, Apple Watch, Garmin, and Whoop, positioning Audicin as an infrastructure-level technology rather than a standalone consumer application.

From wearables to defence: a dual-use commercial strategy

Founded in 2022 by an all-female team — Laura Avonius (CEO), Victoria Williamson, and Mariana Sousa Aguiar — Audicin is pursuing a dual-track commercial strategy that spans consumer wellness and restricted-access environments. A new product in development, a standalone offline Sleep Headband, targets healthcare facilities and defence settings where mobile devices are not permitted. The device delivers pre-configured recovery programmes based on low-frequency brainwave protocols without requiring a connected phone, opening addressable markets that most consumer wellness companies cannot reach.

The company reports strong early commercial traction, with a €6.9 million ($8 million) sales pipeline spanning defence, athletic performance, and wellness clinic sectors. This pipeline figure, notably large relative to the company’s current funding stage, suggests that Audicin’s dual-use approach is resonating with institutional buyers who value evidence-based nervous system interventions delivered through scalable, passive technology.

Finland’s deep tech ecosystem supports neuroscience commercialisation

Audicin’s fundraise is emblematic of a broader trend within Finland’s deep tech ecosystem, where companies are increasingly commercialising technologies rooted in peer-reviewed scientific research. The backing from Business Finland’s Deep Tech Accelerator programme underscores the institutional support available to Finnish startups operating at the frontier of applied neuroscience. For a female-founded company operating in a sector where the gap between scientific capability and commercial product has traditionally been wide, Audicin’s progress from laboratory science to a multi-million-dollar sales pipeline in under four years represents a notable trajectory.

Company: Audicin
HQ: Helsinki, Finland
Founded: 2022
Round: $1.9 million (€1.6 million)
Key Investors: Petteri Lahtela and Virpi Tuomivaara (Oura Health co-founders), Business Finland Deep Tech Accelerator
Total Funding: ~$3 million
Use of Funds: Scaling technology across defence, healthcare, and enterprise applications
Website: audicin.com